Last reviewed · How we verify
PD-1 Monoclonal Antibody
This monoclonal antibody binds to PD-1 on T cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses.
This monoclonal antibody binds to PD-1 on T cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses. Used for Various solid tumors and hematologic malignancies (specific approved indications not definitively established for this institutional candidate).
At a glance
| Generic name | PD-1 Monoclonal Antibody |
|---|---|
| Also known as | Sintilimab, Toripalimab, Tislelizumab, PD-1, MW11 injection |
| Sponsor | Peking University People's Hospital |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
PD-1 is an immune checkpoint receptor that, when engaged by its ligands (PD-L1 or PD-L2), suppresses T cell activation and allows tumors to evade immune surveillance. By blocking this interaction, the antibody releases the brakes on the immune system, enabling T cells to recognize and attack cancer cells. This mechanism is fundamental to checkpoint inhibitor immunotherapy.
Approved indications
- Various solid tumors and hematologic malignancies (specific approved indications not definitively established for this institutional candidate)
Common side effects
- Fatigue
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Rash
- Hypothyroidism
Key clinical trials
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (PHASE2)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma (PHASE2)
- Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (PHASE1)
- A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (PHASE2)
- Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD-1 Monoclonal Antibody CI brief — competitive landscape report
- PD-1 Monoclonal Antibody updates RSS · CI watch RSS
- Peking University People's Hospital portfolio CI